Claims for Patent: 7,585,512

Summary for Patent: 7,585,512

Title:	Composition and method of using tumor cells
Abstract:	The present invention is directed to a treatment for cancer. Compositions and methods of treating cancer are included in the scope of the present invention. The compositions of the present invention include a composition prepared from tumor cells or tumor cell extracts. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a composition comprising tumor cells and/or tumor cell extracts.
Inventor(s):	Berd; David (Wyncote, PA)
Assignee:	Thomas Jefferson University (Philadelphia, PA)
Application Number:	08/203,004
Patent Claims:	1. A method of treating a malignant tumor in a human patient comprising co-administering to the patient (a) a composition comprising a therapeutically effective amount of human tumor cells that: (i) are conjugated to a hapten; (ii) are of the same tumor type as the malignant tumor of said patient for treatment of whom the composition is intended; (iii) are autologous to said patient; and (iv) have been rendered incapable of growing in the body of a human upon injection therein; and (b) an adjuvant; wherein said malignant tumor is from a cancer selected from the group consisting of melanoma cancer, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer; and wherein said administration elicits a delayed-type hypersensitivity response by said patient to tumor cells conjugated to said hapten; and repeating said administration. 2. The method of claim 1, wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl)ethylene diamine. 3. The method of claim 1 wherein said hapten is dinitrophenyl. 4. The method of claim 1, further comprising administering a therapeutically effective amount of cyclophosphamide prior to the first administration of said composition. 5. The method of claim 4 further comprising sensitizing the patient with a therapeutically effective amount of 1-fluoro-2,4-dinitrobenzene prior to administering the thereapeutically effective amount of cyclophosphamide. 6. The method of claim 1 wherein said adjuvant is Bacillus Calmette-Guerin. 7. The method of claim 1 wherein said administration of said composition prolongs survival of said patient. 8. The method of claim 1, wherein said administration of said composition elicits T lymphocytes that infiltrate the tumor of said human.

Details for Patent 7,585,512

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2026-09-08